Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Ramirez, Sydney I.
    • Other Affiliation: La Jolla Institute for Immunology
  • Grifoni, Alba
    • Other Affiliation: La Jolla Institute for Immunology
  • Weiskopf, Daniela
    • Other Affiliation: La Jolla Institute for Immunology
  • Parikh, Urvi M.
    • Other Affiliation: University of Pittsburgh
  • Heaps, Amy
    • Other Affiliation: University of Pittsburgh
  • Faraji, Farhoud
    • Other Affiliation: University of California San Diego
  • Sieg, Scott F.
    • Other Affiliation: Case Western Reserve School of Medicine
  • Ritz, Justin
    • Other Affiliation: Harvard T.H. Chan School of Public Health
  • Moser, Carlee B.
    • Other Affiliation: Harvard T.H. Chan School of Public Health
  • Eron, Joseph J.
    • Affiliation: School of Medicine, Department of Medicine
  • Currier, Judith S.
    • Other Affiliation: University of California, Los Angeles
  • Klekotka, Paul
    • Other Affiliation: Eli Lilly and Company
  • Sette, Alessandro
    • Other Affiliation: La Jolla Institute for Immunology
  • Wohl, David A.
    • Other Affiliation: University of California, Los Angeles
  • Daar, Eric S.
    • Other Affiliation: Harbor-UCLA Medical Center
  • Hughes, Michael D.
    • Other Affiliation: Harvard T.H. Chan School of Public Health
  • Chew, Kara W.
    • Other Affiliation: University of California, Los Angeles
  • Smith, Davey M.
    • Other Affiliation: University of California San Diego
  • Crotty, Shane
    • Other Affiliation: La Jolla Institute for Immunology
Abstract
  • Despite the widespread use of SARS-CoV-2-specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2-specific T cell responses has been unknown, resulting in uncertainty as to whether anti-SARS-CoV-2 mAb administration may result in failure to generate immune memory. Alternatively, it has been suggested that SARS-CoV-2-specific mAb may enhance adaptive immunity to SARS-CoV-2 via a "vaccinal effect." Bamlanivimab (Eli Lilly) is a recombinant human IgG1 that was granted FDA emergency use authorization for the treatment of mild to moderate COVID-19 in those at high risk for progression to severe disease. Here, we compared SARS-CoV-2 specific CD4+ and CD8+ T cell responses of 95 individuals from the ACTIV-2/A5401 clinical trial 28 days after treatment with 700 mg bamlanivimab versus placebo. SARS-CoV-2-specific T cell responses were evaluated using activation induced marker (AIM) assays in conjunction with intracellular cytokine staining (ICS). We demonstrate that most individuals with acute COVID-19 develop SARS-CoV-2-specific T cell responses. Overall, our findings suggest that the quantity and quality of SARS-CoV-2-specific T cell memory was not diminished in individuals who received bamlanivimab for acute COVID-19. Receipt of bamlanivimab during acute COVID-19 neither diminished nor enhanced SARS-CoV-2-specific cellular immunity.
Date of publication
DOI
Identifier
Resource type
  • Article
Journal title
  • JCI Insight
Language
  • English
Version
  • Postprint
Funder
  • National Institute of Allergy and Infectious diseases Department of Health and Human Services (AI036214, AI131385, UM1AI068634, UM1AI068636, and UM1AI106701)
  • John and Mary Tu Foundation, NIH T32 AI007036
  • A.P. Giannini Foundation fellowship award
ISSN
  • 0021-9738

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 163471.1-20221114192405-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf 2022-12-05 Public Download